ZBH
Zimmer Biomet·NYSE
--
--(--)
--
--(--)
ZBH fundamentals
Zimmer Biomet (ZBH) released its earnings on Feb 10, 2026: revenue was 2.24B (YoY +10.90%), beat estimates; EPS was 2.42 (YoY +4.76%), beat estimates.
Revenue / YoY
2.24B
+10.90%
EPS / YoY
2.42
+4.76%
Report date
Feb 10, 2026
ZBH Earnings Call Summary for Q4,2025
- Revenue Growth: Q4 2025 organic growth 5.4%, U.S. 5.7%, driven by new products and ASC expansion. 2026 guidance: 1-3% growth amid sales force transition.
- Sales Force Transformation: Shifting to dedicated reps by 2027, with 200+ new hires in high-growth areas. 2026 disruption expected, but 2027+ productivity gains anticipated.
- Financial Highlights: 2025 free cash flow $1.172B (11% YoY). 2026 EPS $8.30-$8.45, with 8-10% free cash flow growth.
- Strategic Initiatives: ASC penetration ~20%, mBos robot launch, and iodine-coated implants for Japan. Focus on operational efficiency and shareholder returns.
EPS
Actual | 1.6492 | 0.0485 | 1.7559 | 2.047 | 1.6589 | 1.8432 | 1.7559 | 1.8917 | 1.61 | 1.82 | 1.58 | 1.88 | 1.89 | 1.82 | 1.65 | 2.2 | 1.94 | 2.01 | 1.74 | 2.31 | 1.81 | 2.07 | 1.9 | 2.42 | |||||||||||||||
Forecast | 1.3897 | -0.6857 | 1.0366 | 2.0011 | 1.4828 | 1.8032 | 1.7037 | 1.917 | 1.4023 | 1.641 | 1.5542 | 1.8276 | 1.6386 | 1.818 | 1.5978 | 2.1536 | 1.8704 | 1.991 | 1.7439 | 2.2953 | 1.7707 | 1.9788 | 1.866 | 2.398 | |||||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +18.67% | +107.07% | +69.39% | +2.29% | +11.88% | +2.22% | +3.06% | -1.32% | +14.81% | +10.91% | +1.66% | +2.87% | +15.34% | +0.11% | +3.27% | +2.15% | +3.72% | +0.95% | -0.22% | +0.64% | +2.22% | +4.61% | +1.82% | +0.92% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.78B | 1.23B | 1.93B | 2.09B | 1.85B | 2.03B | 1.92B | 2.04B | 1.66B | 1.78B | 1.67B | 1.83B | 1.83B | 1.87B | 1.75B | 1.94B | 1.89B | 1.94B | 1.82B | 2.02B | 1.91B | 2.08B | 2.00B | 2.24B |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.82B | 921.26M | 1.71B | 2.08B | 1.76B | 1.97B | 1.94B | 2.07B | 1.59B | 1.72B | 1.63B | 1.76B | 1.70B | 1.83B | 1.75B | 1.93B | 1.87B | 1.94B | 1.80B | 2.01B | 1.90B | 2.06B | 2.01B | 2.22B |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1.72% | +33.09% | +12.77% | +0.21% | +5.06% | +2.67% | -0.99% | -1.40% | +4.88% | +3.48% | +2.18% | +3.64% | +7.42% | +2.36% | +0.27% | +0.61% | +1.16% | +0.10% | +1.44% | +0.44% | +0.73% | +1.00% | -0.52% | +0.90% |
Earnings Call
You can ask Aime
What factors drove the changes in Zimmer Biomet's revenue and profit?What is Zimmer Biomet's latest dividend and current dividend yield?What is the market's earnings forecast for Zimmer Biomet next quarter?What guidance did Zimmer Biomet's management provide for the next earnings period?What does Zimmer Biomet do and what are its main business segments?What is the revenue and EPS growth rate for Zimmer Biomet year over year?Did Zimmer Biomet beat or miss consensus estimates last quarter?What were the key takeaways from Zimmer Biomet's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
